The professor is casual and relaxed. It’s the beginning of November 2014 and in mediakademie.de, an online service providing continuing medical education, the class is covering a very serious issue: stroke prevention. The moderator was just asked the question whether the new anticoagulants are “actually really easy to use.”
“Easy as it gets,” the professor said, explaining: “One pill in the morning and one in the evening verifies renal function.” Discontinue the medication before any surgery, and then “begin a day after an operation.” That’s all you need to “switch on and off clotting, so to speak,” he said.
So that viewers understand what this is all about, the man mentions the active ingredient — dabigatran — every now and then. This is the core ingredient of the anticoagulant Pradaxa, a top revenue generator for Mainz-based pharmaceutical maker Boehringer Ingelheim.
Conveniently, the company also operates mediakademie.de.